These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 17122007

  • 1. Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance.
    Halfon P, Trepo E, Antoniotti G, Bernot C, Cart-Lamy P, Khiri H, Thibaud D, Marron J, Martineau A, Pénaranda G, Benmoura D, Blanc B, RBML (Réseau de Biologie Moléculaire Libérale).
    J Clin Microbiol; 2007 Feb; 45(2):313-6. PubMed ID: 17122007
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.
    Sandri MT, Lentati P, Benini E, Dell'Orto P, Zorzino L, Carozzi FM, Maisonneuve P, Passerini R, Salvatici M, Casadio C, Boveri S, Sideri M.
    J Clin Microbiol; 2006 Jun; 44(6):2141-6. PubMed ID: 16757611
    [Abstract] [Full Text] [Related]

  • 3. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
    Carozzi F, Bisanzi S, Sani C, Zappa M, Cecchini S, Ciatto S, Confortini M.
    J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
    [Abstract] [Full Text] [Related]

  • 4. Human papillomavirus (HPV) in atypical squamous cervical cytology: the Invader HPV test as a new screening assay.
    Wong AK, Chan RC, Nichols WS, Bose S.
    J Clin Microbiol; 2008 Mar; 46(3):869-75. PubMed ID: 18174309
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
    De Francesco MA, Gargiulo F, Schreiber C, Ciravolo G, Salinaro F, Manca N.
    J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
    [Abstract] [Full Text] [Related]

  • 6. A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study.
    Wentzensen N, Gravitt PE, Solomon D, Wheeler CM, Castle PE.
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1341-9. PubMed ID: 19423515
    [Abstract] [Full Text] [Related]

  • 7. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA Genotyping assay to screen the discordant results.
    Mo LZ, Monnier-Benoit S, Kantelip B, Petitjean A, Riethmuller D, Prétet JL, Mougin C.
    J Clin Virol; 2008 Feb; 41(2):104-10. PubMed ID: 18036888
    [Abstract] [Full Text] [Related]

  • 8. comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders.
    van Ham MA, Bakkers JM, Harbers GK, Quint WG, Massuger LF, Melchers WJ.
    J Clin Microbiol; 2005 Jun; 43(6):2662-7. PubMed ID: 15956381
    [Abstract] [Full Text] [Related]

  • 9. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
    Basu P, Banerjee D, Mittal S, Dutta S, Ghosh I, Chowdhury N, Abraham P, Chandna P, Ratnam S.
    J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
    [Abstract] [Full Text] [Related]

  • 10. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
    Bhatla N, Dar L, Patro AR, Kumar P, Kriplani A, Gulati A, Iyer VK, Mathur SR, Sreenivas V, Shah KV, Gravitt PE.
    Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
    [Abstract] [Full Text] [Related]

  • 11. Pap cytopathology and the presence of high-risk human papillomavirus in SurePath liquid preservative and Digene cervical sampler specimens.
    Kapala J, Jang D, Patel J, Biers K, Smieja M, Chernesky M.
    J Virol Methods; 2007 Jun; 142(1-2):223-5. PubMed ID: 17320978
    [Abstract] [Full Text] [Related]

  • 12. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
    Nieves L, Enerson CL, Belinson S, Brainard J, Chiesa-Vottero A, Nagore N, Booth C, Pérez AG, Chávez-Avilés MN, Belinson J.
    Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
    [Abstract] [Full Text] [Related]

  • 13. Analytical evaluation of the PapilloCheck test, a new commercial DNA chip for detection and genotyping of human papillomavirus.
    Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C.
    J Virol Methods; 2009 Mar; 156(1-2):77-83. PubMed ID: 19041893
    [Abstract] [Full Text] [Related]

  • 14. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study.
    Gravitt PE, Schiffman M, Solomon D, Wheeler CM, Castle PE.
    Cancer Epidemiol Biomarkers Prev; 2008 May; 17(5):1248-54. PubMed ID: 18483347
    [Abstract] [Full Text] [Related]

  • 15. Retrospective and prospective evaluation of the Amplicor HPV test for detection of 13 high-risk human papillomavirus genotypes on 862 clinical samples.
    Poljak M, Fujs K, Seme K, Kocjan BJ, Vrtacnik-Bokal E.
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Dec; 14(4):147-52. PubMed ID: 16435043
    [Abstract] [Full Text] [Related]

  • 16. HPV Prevalence in the Dutch cervical cancer screening population (DuSC study): HPV testing using automated HC2, cobas and Aptima workflows.
    Huijsmans CJ, Geurts-Giele WR, Leeijen C, Hazenberg HL, van Beek J, de Wild C, van der Linden JC, van den Brule AJ.
    BMC Cancer; 2016 Nov 28; 16(1):922. PubMed ID: 27894291
    [Abstract] [Full Text] [Related]

  • 17. The clinical value of digene hybrid capture HPV DNA testing in a referral-based population with abnormal pap smears.
    Recio FO, Sahai Srivastava BI, Wong C, Hempling RE, Eltabbakh GH, Piver MS.
    Eur J Gynaecol Oncol; 1998 Nov 28; 19(3):203-8. PubMed ID: 9641214
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions.
    Kang WD, Kim CH, Cho MK, Kim JW, Kim YH, Choi HS, Kim SM.
    Int J Gynecol Cancer; 2009 Jul 28; 19(5):924-8. PubMed ID: 19574786
    [Abstract] [Full Text] [Related]

  • 19. [Evaluation of gene chip technology for high risk type human papillomavirus in cervical cancer screening].
    Li RZ, Shi JF, Zhou QZ, Wu RF, Li N, Wu LN, Zhou YQ, Wang Q, Liu ZH, Liu B, Qiao YL.
    Zhonghua Yi Xue Za Zhi; 2006 Feb 07; 86(5):307-11. PubMed ID: 16677522
    [Abstract] [Full Text] [Related]

  • 20. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
    Nakamura M, Nakade K, Orisaka S, Iwadare J, Mizumoto Y, Fujiwara H.
    Am J Clin Pathol; 2019 Feb 04; 151(3):263-269. PubMed ID: 30260388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.